Clinical trials
Metastatic Ovarian Cancer clinical trials
Below are recruiting metastatic ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 237 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05952453RecruitingPhase 2
New ovarian cancer treatment with chemo plus maintenance medicines
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT07299409RecruitingPhase 2
Study of sacituzumab govitecan for advanced triple-negative breast cancer
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
Vancouver, British ColumbiaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07673861Recruiting
Using ctDNA to find resistance and guide cancer treatment
This trial uses a simple blood test to look for changes in your cancer's DNA that might show why your current treatment stopped working. The results could help your doctor choose your next treatment more precisely.
LondonAges 18 years+ - NCT07403630Recruiting
Tumor chemogenomic profiler for cancer patients of all ages
This trial uses a new testing platform to analyze the genes and proteins in your tumor, aiming to find the most effective treatments for people with cancer that has come back, is not responding to treatment, or has spread. It is designed for both children and adults with any type of blood cancer or solid tumor.
Palermo, PalermoAges 1 year+ - NCT06963723Recruiting
Screening for financial hardship in advanced cancer
This study screens people with advanced cancer for financial problems. It aims to see if catching these problems early can improve your care and well-being.
Phoenix, ArizonaAges 21 years+ - NCT07613723RecruitingPhase 1
Testing ZI-MA4-1 immunotherapy for advanced solid cancers
This early-stage trial tests a new type of immunotherapy called ZI-MA4-1 in patients with advanced cancers (ovarian, lung, synovial sarcoma, or head and neck) that have stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells that have a specific protein called MAGE-A4.
LondonAges 18–75 - NCT05927818Recruiting
Test a sentinel lymph node biopsy in early ovarian cancer
This trial studies whether taking a sample from the sentinel lymph node during surgery can help with staging early ovarian cancer. It may help doctors find spread to lymph nodes more accurately while limiting unnecessary lymph node removal in some cases.
Istanbul, TurkeyAges 18–90 - NCT06450314RecruitingPhase 2
De-escalating treatment for advanced HER2-positive breast cancer
This trial tests whether it's safe to reduce or stop some cancer treatments for people whose advanced HER2-positive breast cancer has been well-controlled for at least 2 years and has no detectable cancer cells in blood tests.
RennesAges 18 years+ - NCT07670312RecruitingPhase 1/Phase 2
Testing XYA02 for advanced solid tumors
This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.
Sydney, New South WalesAges 18 years+ - NCT07318389RecruitingEarly Phase 1
Tracking tumor resistance in metastatic colorectal cancer
This trial studies how colorectal cancer that has spread becomes resistant to treatment. By taking biopsies over time, researchers hope to find new ways to target the cancer and help patients live longer.
Houston, TexasAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT04847063RecruitingPhase 1
Test drug heating inside the abdomen for peritoneal cancer
This Phase 1 trial tests a treatment that delivers heated chemotherapy directly into the abdomen (HIPEC) for certain cancers that have spread only within the abdominal lining. It aims to see how safely and effectively this approach works, especially when doctors can remove as much tumor as possible.
Bethesda, MarylandAges 18–120 - NCT07050771RecruitingPhase 2
Prehabilitation before cancer surgery study
This trial tests a comprehensive program of exercise, nutrition, and wellness support before and after major cancer surgery. It aims to help patients recover faster and better, whether or not they also receive chemotherapy or radiation before surgery.
Houston, TexasAges 18 years+ - NCT05104515RecruitingPhase 1
First cancer vaccine test for advanced lung, ovarian, or prostate cancer
This Phase 1 study tests OVM-200, a new cancer vaccine, to see how it is tolerated and how it affects the immune system in people with advanced NSCLC, ovarian cancer, or prostate cancer. You may be eligible if your cancer has already had approved treatment(s) and no further standard options are planned within the first two months.
London, LondonAges 18–75 - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT07708753RecruitingPhase 3
Study of a new drug for advanced ovarian cancer that stopped responding to platinum
This study tests a new drug called SYS6043 for advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It aims to see if this drug can help when other treatments have not worked.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05329532RecruitingPhase 1/Phase 2
Modi-1 cancer vaccine for several hard-to-treat cancers
This Phase 1/2 study tests a cancer vaccine called Modi-1 Moditope in people with advanced triple-negative breast cancer, head and neck cancer, ovarian/high-grade serous cancer, or kidney cancer. It aims to help the immune system better recognize and attack the cancer.
Brighton, DefaultAges 18 years+ - NCT06513624RecruitingPhase 1
ETC-159 plus pembrolizumab for advanced ovarian cancer
This trial tests a new combination of two drugs—ETC-159 (a pill that targets a specific growth pathway) and pembrolizumab (an immunotherapy)—for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Singapore, SingaporeAges 21–99 - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Loma Linda, CaliforniaAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+
Hear when a new Metastatic Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic ovarian cancer?
- Yes. Clin2 currently lists 237 recruiting metastatic ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.